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Novel target development for immune-based cancer therapies is an active area of 
clinical interest. NKG2D is an activating immune cell receptor highly expressed on the 
surface of cytolytic natural killer (NK), NKT, and T-cells, making NKG2D an excellent target 
for immune therapy. Our lab developed a novel bispecific killer-cell engager antibody (BiKE) 
targeting human NKG2D and CS1 receptors highly expressed in multiple myeloma (MM). 
BiKE binds to human NKG2D receptors, activating lymphocyte effector cells while binding 
and lysing CS1-expressing MM tumors (Fig. 1). BiKE does not bind murine NKG2D, so human 
lymphocytes and activating cytokines are injected to test BiKE in our orthotopic immune 
deficient mouse model. However, exogenous cytokines, such as IL-2 and IL-15, can also 
activate NK cell cytotoxicity, making it difficult to distinguish BiKE-mediated NK killing from 
cytokine-mediated killing. Our in vitro studies demonstrate that BiKE activates lymphocytes 
and lyses CS1-expressing tumors, but an immune competent mouse model with NK, NKT and 
T-cells expressing human NKG2D is needed to reliably assess BiKE efficacy in vivo.  
 
In humans, NKG2D triggers NK cell activation by associating with adaptor protein 
DAP10, initiating cell cytotoxicity and IFN-γ release. In mice, NKG2D signals through DAP10 
and DAP12, controlling cell cytotoxicity and IFN-γ release, respectively. The murine NKG2D 
transmembrane domain conveys adaptor protein specificity, allowing association with both 
DAP10 and DAP12. We have shown that substituting human NKG2D for mouse NKG2D does 
not elicit activation signals, likely due to DAP10/12 differences between species. 
Consequently, we created a chimeric NKG2D construct to evaluate BiKE efficacy in murine 
NK cells. Overall, we hypothesize that a chimeric NKG2D construct with a human 
NKG2D ectodomain and mouse NKG2D transmembrane and intracellular domain will 
bind BiKE, initiating both cell cytotoxicity and IFN-γ release similar to human NKG2D. 
After creating our chimeric protein vector, we expressed it in both a murine liver NK 
(LNK) cell line and primary murine NK cells to test cell cytotoxicity. Our results in the LNK 
cell line did not show specific lysis of MM tumor cells, but the primary murine NK cells did 
show significant MM lysis (p=0.0039). During our testing, we determined an error in the 
protein binding domains of our chimeric protein and redesigned it. Using our new chimeric 
vector, we transiently expressed chimeric NKG2D in 293T cells, showing binding with anti-
human NKG2D antibodies and BiKE. In this study, we show that a chimeric NKG2D receptor 
can bind human NKG2D ligands and initiate a cytotoxic tumor lysis response. While there is 
still testing to be done, we are confident moving forward that our redesigned chimeric 






Multiple Myeloma Cancer: An Overview 
Multiple Myeloma (MM) is a cancer of the plasma cells, or differentiated B cells in the 
bone marrow (1). Typically B cells are only stimulated to form plasma cells when the 
immune system is fighting an infection, as plasma cells produce antibodies to neutralize and 
target foreign antigens (2). However, in MM this process becomes dysregulated and plasma 
cells begin overcrowding the rest of the bone marrow and producing high levels of M protein, 
a non-specific antibody (2). The high levels of M protein in the blood stream make the blood 
thicker, placing stress on the kidneys that, coupled with the high levels of calcium also 
characteristic of MM, leads to renal failure (3). In addition, the plasma cells crowd out other 
cells in the bone marrow critical to bone marrow function, including red blood cell 
precursors, white blood cell precursors, and platelets, leading to anemia, increased 
susceptibility to infection, decreased clotting ability, and a disrupted bone marrow 
microenvironment (2). Plasma cells also secrete osteoclast-activating factors (OAF) that 
activate osteoclasts in the bone marrow to break down bone tissue faster than the bone can 
be reformed, resulting in weak and brittle bones in many MM patients (4). Combined 
together, these symptoms prove to be formidable to treat and physicians often face 
challenges balancing current treatments with renal failure, anemia, and brittle bones. 
MM accounts for nearly 10% of all hematological cancers, but the five-year survival 
rate is only 49.6%. While MM is a rare cancer, in 2017 over 30,000 people were diagnosed 
with MM and nearly 13,000 MM deaths were recorded. Median diagnosis age for MM is 69, 
with African-American men having the highest risk for developing MM and mortality (5). 
Unlike other cancers, patients are never considered cured and recurrent multiple myeloma 
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poses a significant clinical challenge for physicians due to damage to the kidneys and other 
organs as well as aggressive MM tumors (6). In light of these findings, MM has been a 
significant focus of clinical and benchtop research to address the unique needs of MM 
patients. 
Current Multiple Myeloma Treatments 
Once diagnosed with MM, most patients will undergo autologous stem cell transplant 
(ASCT). Hematopoietic stem cells are collected from patient bone marrow and then 
chemotherapy is used to kill all cells in the bone marrow, both malignant and normal cells. 
The healthy stem cells are then reintroduced to the patient to regenerate the blood cells in 
the bone marrow. While this treatment has a low mortality rate, most patients will relapse 
within two years because many cancerous stem cells are reintroduced to the patient during 
this process. Recent studies have shown that undergoing two ACST treatments six to twelve 
months apart can reduce the rate of relapse for patients, and Attal et. al. showed that the 
seven-year event free rate for patients with double ACST (20%) doubled from the control 
singular ASCT treatment (10%). However, this treatment has shown to be riskier for patients 
with the potential for more side effects and cancer relapse and, as a result, is not widely 
utilized (7).  
If ACST transplant is not a viable option, allogeneic stem cell transplantation (allo-
SCT) is considered. In this treatment, a matched donor donates their bone marrow to a MM 
patient. This approach is attractive because currently this is the only therapy that can cure 
MM. The tissue graft replaces cancerous plasma cells in the patient and studies have found 
that Graft Versus Host Disease (GVHD), a common side effect to tissue transplants when the 
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body rejects a tissue graft, can actually lead to the better overall survival of MM patients by 
mounting an immune response in the bone marrow. However, there is a high rate of 
treatment-related mortality, which discourages many doctors and patients from using this 
treatment plan. As a result, this treatment is only recommended for “ultra-high risk” MM, 
typically patients with genetic abnormalities that put them at risk for aggressive MM tumors 
(8). 
In addition to traditional tissue grafts and chemotherapy, research during the past 
fifteen years has discovered several promising drugs that, when used in combination with 
other therapy techniques, hold promise for MM patients. One such drug is bortezomib, the 
first FDA-approved proteasome inhibition drug for cancer therapy. Unlike other 
chemotherapy drugs, bortezomib functions by reversibly inhibiting the 26S proteasome in 
the cell which disrupts protein degradation in the cell critical for maintaining cell cycle 
control; buildup of these cell cycle control proteins lead to apoptosis. Since MM tumors 
already have dysregulated cell cycle signal proteins, they are particularly susceptible to 
bortezomib. Bortezomib also has MM specific mechanisms, including preventing the 
breakdown of inhibitory kappa B which stabilizes the nuclear factor kappa B(NFkB) complex 
and prevent its further downstream signaling in MM cells. NFkB has been shown to promote 
MM tumor growth and decrease tumor cell dependence on the bone marrow 
microenvironment, making inhibiting NFkB signaling a clinically relevant treatment option 
(9). Treatment with bortezomib also decreases tumor cell adhesion, leading to apoptosis, 
and disrupts survival cytokine signals through IL-6, IGF-1, VEGF, and TNF-α. In addition to 




Bortezomib has been shown to be clinically effective when combined with the current 
chemotherapy drug dexamethasone, improving patient response rates up to 62% (10). Many 
studies indicate that bortezomib increases natural killer (NK) cell activity in MM tumor 
rejection by increasing MM tumor expression of MHC class 1 activating ligands and 
sensitizing the tumors to NK-mediated lysis, which will be discussed in the next section (11). 
Relapsed or non-transplant eligible MM patients can also take advantage of bortezomib, but 
patients suffering from renal failure may have to stop treatment due to renal complications. 
While it shows promise, bortezomib is currently only approved for recurrent MM patients 
or those ineligible for transplantation, so further drugs are needed on the market to address 
this need (10). 
Natural Killer Cells 
Natural Killer (NK) cells are a critical part of the body’s immune response to detect 
and destroy infections. Unlike the T and B cells of the adaptive immune system, NK cells are 
large granular lymphocytes in the innate immune system, meaning that they do not adapt to 
new foreign antigens and they have a larger range of activation signals than cells in the 
adaptive immune system. NK cells continuously patrol the body until they encounter a 
source of infection, where a wide variety of activating receptors on the cell surface designed 
to detect large classes of foreign invaders are engaged. Lymphocytes of the adaptive immune 
system typically have restricted targets due to the unique activating receptors found on their 
cellular surface, such as with T cells, but NK cells are able to identify a wide range of stress 
ligands induced on host cells due to infection by foreign microbes, including major 
histocompatibility complex (MHC) class-1-chain-related–proteins (MICA & MICB) and 
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cytomegalovirus UL16-binding proteins (ULBPs) in humans and histocompatibility antigen 
60 (H60), retinoic acid earl inducible cDNA clone-1 (Rae-1), and murine UL16-binding 
protein-like transcript 1 (MULT1) in mice. NK cells then respond to microbes similarly to T 
cells, causing target cell lysis and cytokine secretions to attract other lymphocytes to the 
infection site. Most notably, NK cells secrete IFNγ, a cytokine which, in addition to activating 
other NK cells, also helps mount a T cell immune response, activates antigen-presenting cells 
to upregulate MHC class ligands, activates macrophage-mediated cell killing, and prevents 
the proliferation of infected host cells (12). Both the wide-sweeping antigen recognition and 
cytotoxic response to infection make NK cells a key player in the immune system. 
In humans, NK cells are typically defined by the expression of CD56, a 140 kDa neural 
cell adhesion molecule, and the absence of CD3, a cluster of differentiation 3 receptor 
expressed exclusively on T-cells. NK cells are hypothesized to develop in the lymph nodes 
and tonsils, allowing ready access to the circulation system, and are relatively short lived 
when compared to other granular lymphocytes. There are two major classes of NK cell 
development, CD56bright (cells with high expression of CD56) and CD56dim NK cells (cells with 
low expression of CD56). CD56bright cells are hypothesized to be the earlier stage of NK cell 
development in the secondary lymphocyte tissues with an increased capacity to secrete IFNγ. 
CD56bright cells mature into CD56dim cells with increased cytolytic capacity in the circulation 
system. NK cells have several pathways to induce a cytolytic response, mediated by NKG2D, 
NCR, NKp80, and nectin and nectin-like receptors. NK cells also have many inhibitory 
pathways to balance NK cell activity, including killer immunoglobulin-like receptors (KIRs) 
which recognize MHC class ligands or ‘self-molecules’ only expressed on host cells to 
distinguish host cells from foreign microbes and prevent NK cells from killing uninfected 
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host cells(13). The powerful cytolytic response activity and simple activation pathways have 
made NK cells a topic of intensive research as a critical piece of the immune system and as 
an attractive clinical target for immunotherapy. 
Immune Evasion 
Cancerous plasma cells (PC) express adhesion molecules that aid their binding with 
the bone marrow stromal cells (BMSC) in the marrow microenvironment. This adhesion 
activates IL-6 production and secretion in BMSC cells, which activates a paracrine IL-6 
pathway leading to PC transcription and secretion of IL-6 which continues signaling to PC 
cells in an autocrine fashion. Tumor necrosis factor alpha (TNF-α) also contributes to this 
signaling cycle; by binding to BMSC cells, it also signals for IL-6 secretion and the expression 
of adhesion molecules. High levels of IL-6, in turn, decrease the number of regulatory T cells 
(Treg) while increasing the number of IL-17 producing T cells (Th17). This increase in IL-17 
increases osteoclast activity and leads to the further development of lytic bone disease. MM 
tumor cells also express an IL-17 receptor, causing the Th17 pro-inflammatory response to 
further fuel tumor growth and development. Th17 cells also inhibit the actions of Th1 T-cells, 
which typically support cytotoxic CD8+ T cells in rejecting cancerous cells (14,15). With 
decreased Th1 activity, MM prevents tumor surveillance and suppressing the body’s immune 
response (14).  
NK and NKT cells have also been implicated in MM tumor progression; studies have 
documented that NK cell differentiation is impaired in addition to functionality, primarily as 
a decrease of IFNγ production even in the presence of activating NK cell ligands. However, 
studies have documented that this response can be overcome, particularly by injecting 
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priming dendritic cells expressing α-GalCer, an activating NKT ligand (16). IL-6 decreases 
NK cell cytotoxicity as does transforming growth factor-beta (TGF-β), another prominent 
immune system regulator expressed by MM. TGF-β decreases the number of cytolytic 
granules in NK cells, inhibiting NK cell functionality via the CD16 receptor activating and 
antibody dependent cellular cytotoxicity (ADCC) pathways. The immunoglobulins produced 
by the MM plasma cells also decrease cytolytic granules, but research has shown that this 
effect can be reversed via IL-2 signaling (17). IL-15 is another cytokine important to the 
activation of NK cells, but, much like IL-17 mentioned above, MM cells express IL-15 
receptors and use these signals to fuel their own tumor growth. Like many cancers, MM has 
been shown to shed ligands for NKG2D and other activating receptor on NK cells, leading to 
a downregulation in these receptors; this pathway will be discussed in more detail under the 
NKG2D heading (18). These results show that, while MM has manipulated the tumor 
microenvironment to inhibit immune surveillance and even uses cytokines to fuel tumor 
growth, the immune system can be retargeted to clear tumor cells. 
Immunotherapy and Natural Killer Cell Multiple Myeloma Therapy 
MM research in the last decade has primarily focused on redirecting the patient’s 
immune system to attack MM tumors. The recent wealth of knowledge in the field of 
immunology has guided translational immunotherapy cancer research. Researchers are 
attempting to redirect or reactivate the body’s natural immune defenses by targeting 
immune cells to directly attack cancer tumors. By specifically targeting tumor cells with the 
immune system, researchers aim to reduce the off-target side effects of common 
chemotherapy drugs and lead to specific apoptosis of cancerous cells. Combined with 
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currently available cancer treatment techniques, these therapies hold much promise and 
have been areas of intensive clinical and research interest. 
Perhaps the most successful class of immunotherapy drugs is the chimeric antigen 
receptor (CAR) used with T cells. Initially, CAR T cells were used to put acute lymphoblastic 
leukemia patients into complete remission, but this therapy has expanded into MM 
treatment. After initial chemotherapy and ASCT, a patient’s T cells are isolated and 
transduced to express a CD19-specific chimeric antigen that targets MM tumors. While CD19 
is reported to be expressed infrequently on MM cells, studies show that some drug-resistant 
strains of MM express CD19, making these receptors an excellent target for CAR therapy. 
Using the CAR design, the receptor contains an intracellular T cell activation domain, a 
costimulatory domain, and an antigen recognition domain, in this case specific to CD19. 
These T cells then specifically target MM cells expressing CD19 ligands, initiate cell 
cytotoxity and IFNγ release, and lead to complete cancer remission (19). Similar projects 
have focused on a B-cell maturation antigen target for MM, but these clinical trials did not 
show the same level of mounting immune response as the CD19 CAR trial (20).  
One disadvantage to the CD19 CAR therapy is that studies have found over 95% of 
MM patients do not CD19 expression on MM tumor cells, meaning many patients cannot take 
advantage of this treatment (21). In addition, this therapy places patients at risk for cytokine-
release syndrome (CRS), which occurs when large numbers of the immune system effector 
cells are stimulated simultaneously and begin releasing activating cytokines, leading to 
further activation of the immune system and severe symptoms for patients. Patients with 
CRS can have fever, nausea, chills, hypotension, kidney dysfunction, respiratory arrest, and 
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Graft vs Host Disease, and some cases have even ended in patient mortality (21,22). While 
steroids and blocking antibodies can be administered to reduce the symptoms and severity, 
CRS remains a critical concern of immunotherapy and in particular the CD19 CAR clinical 
trials. In most cases these symptoms are manageable, but some patients may experience life-
threatening symptoms, making this a leading cause of concern in immunotherapy (23). 
While CAR T cell therapies have shown strong potential, CAR NK cell therapies have 
been largely unexplored and pose a solution to many of the side effects of CAR T cell 
therapies. Our lab has previously created and tested a CS1-specific MM CAR NK cell therapy 
in vivo and in vitro. CS1 is a receptor specifically and highly expressed on the surface of MM 
tumor cells with low expression on B, NK, and T cells. Clinical studies have also found that 
CS1 remains highly expressed on MM patients even in remission, making it an excellent 
target for MM treatment. While CS1 function in normal plasma cells is unknown, in cancerous 
MM cells is hypothesized to promote cell adhesion, the growth of tumors, and interactions 
with BMSCs (21,24). This CS1 CAR therapy demonstrated specific MM cell lysis and proves 
to be a promising direction for clinical trials. In addition, NK cells have the added advantage 
of decreasing CRS, tumor lysis syndrome, graft versus host disease, and off-tumor effects; NK 
cells do not exhibit clonal expansion in vivo like T cells, limiting the response of NK cells to 
prevent side effects (21). NK cells also do not need to be primed as part of the innate immune 
system, meaning that activating cytokines may not need to be injected as part of CAR NK cell 
therapy which could prevent NK cells from becoming overactive and causing patient side 
effects. Combined with previous reports that NK cell activity is impaired in the progression 
of MM, this therapy shows promise at redirecting NK cells to reject cancer tumors but has 
yet to pass clinical trials or be approved by the FDA. 
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Finally, bispecific T-cell engager proteins (BiTE) have shown significant potential in 
retargeting immune effector cells to attack cancer tumors. This molecule consists of two 
single-chain variable antibody fragments connected by a linker. One of these chains will 
target an activating receptor on an immune effector cell, such as T cells, and the other chain 
will target a marker or receptor on cancerous cells. By linking together the single-chain 
variable fragments of two different antibodies, BiTE can activate cytotoxic T-cells, 
specifically bring them into direct contact with cancerous cells, and initiate tumor cell lysis. 
The most successful bispecific antibody fusion protein treatment is the bispecific T-cell 
engager (BiTE) protein produced by Amgen, which is the first BiTE to be approved by the 
FDA. Designed for the treatment of B cell leukemia, it connects CD3 and CD19 receptors on 
T-cells with specific cancer targets, but this treatment only activates T-cells to reject cancer 
(25). The modular design of BiTE allows drug companies and researchers to change out the 
antibody fragments to target different receptors and markers, making BiTE proteins the 
focus of intensive clinical cancer research as a potential therapeutic drug. 
While BiTE 
molecules activate T-cells, 
some researchers are 
creating bispecific killer-
cell engager proteins 
(BiKE), using the same 
modular design of BiTE but 
targeting NK cell activation 
instead of T-cells. Various BiKE proteins have shown to be effective at rejecting cancer 
Figure 1. BiKE specifically binds to NK, NKT and T cells and CS1-expressing tumor cells, 
forming a link between the two cells, activating NK/T cells, and lysing tumor cells. 
Figure 1. BiKE Mechanism 
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tumors in many different cancer lines, but few have passed through clinical trials. One BiKE 
has successfully been tested in the treatment of acute myeloid leukemia (AML) using the 
single-chain variable fragment for the activating CD16 receptor on NK cells and the single-
chain variable fragment for the AML antigen CD33. This BiKE therapy was shown to 
effectively redirect NK cell activity that had been suppressed in AML patients and led to 
tumor cell lysis regardless of disease stage, but the drug has yet to proceed to clinical trials 
(26). The advantage of BiKE over other immunotherapy treatments is its off-the-shelf 
therapy design; BiKE does not need to be modified for individual patients, thus making the 
treatment quicker, cheaper, and readily available for a wider range of cancer patients. In 
addition, the modular design of BiKE simplifies the drug creation process and makes it easy 
to modify BiKE as new cancer targets and activating receptors are discovered (27). Our lab 
has focused on the potential of BiKE in MM therapy and how to take advantage of a wide 
range of immune effector cells in our drug design (Fig. 1). 
Multiple Myeloma BiKE Treatment 
Our lab has created a BiKE therapy using an 
anti-CS1 and anti-NKG2D single-chain variable 
antibody fragments connected via a linker to direct 
the immune system to attack MM cancer cells (Fig. 
2). As mentioned above, CS1 is a glycoprotein 
specifically expressed on the surface of MM tumor 
cells (28). NKG2D is an immune system activating 
receptor found on the surface of three types of killer cells, NK, T, and NKT cells (13). BiKE 
Figure 2. BiKE is composed of the single-chain 
variable fragment of anti-NKG2D and anti-CS1 
antibodies connected by a flexible linker. 
Figure 2. BiKE Structure 
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physically brings together several types of immune 
effector lymphocytes into direct contact with MM 
tumor cells while simultaneously activating tumor cell 
lysis and IFNγ release (Fig. 3). IFNγ is a cytokine 
released by effector lymphocytes to recruit and activate 
nearby immune effector cells, creating a second wave 
of MM cancer cell lysis. Unlike other BiKE or CAR 
therapies, our BiKE antigen would activate a wide 
range of immune effector cells, such as NK, NKT, and CD8(+) αβ and γδ T-cells, generating a 
larger tumor rejection response while simultaneously limiting CRS side-effects; due to the 
57 kDa size, BiKE can be filtered out of the bloodstream and limit long-term activating 
immunotherapy side effects characteristic of other immunotherapies. Studies show that the 
kidneys filter plasma proteins less than 60 kDa out of plasma, allowing BiKE to filter out of 
the bloodstream (29). These concerted efforts would overcome the suppressive tumor 
microenvironment and lead to MM cell lysis and tumor rejection while reducing patient 
safety concerns. 
Our in vitro studies show that BiKE activates the NKG2D receptor on NK, NKT, and 
CD8(+) αβ and γδ T-cells while putting these effector cells in direct contact with MM via the 
CS1 receptor. This interaction leads to the specific lysis of CS1-expressing tumor cells and 
the production of IFNγ. Taken together, this data suggests that BiKE would be an effective 
anti-neoplastic drug against MM in vivo by uniquely engaging three different types of 
lymphocyte effector cells to reject MM tumors. To the best of our knowledge, no other 
immunotherapy drug has attempted to target multiple subsets of lymphocyte effector cells, 
Figure 3. Human NK cells specifically lyse 
a CS1-expressing MM cell line when 
cocultured with BiKE. 
Figure 3. BiKE Tumor Lysis 
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setting our BiKE apart from other drugs and potentially providing patients with another 
effective treatment for MM.  
In Vivo BiKE Testing 
While our in vitro data shows that BiKE would be an effective drug, our in vivo 
modeling system presents several confounding variables that cloud the quality of our data. 
Human NKG2D, the activating receptor for NK cells in BiKE, has both signaling and 
biochemical dissimilarities between humans and mice, making our human BiKE protein 
unable to bind with murine NKG2D. As a result, to test our compound we must inject human 
NK cells into our mouse model so we can observe the tumor rejecting effects between BiKE 
and human NK cells. Our current model irradiates NSG mice to destroy the endogenous 
immune system and then injects MM tumor cells (MM1.s cell line) into the mice. On day 
seven, the mice are then injected with human NK cells isolated from PBMC. Following this, 
each day the mice are injected with BiKE, as well as human IL-2 to promote human NK cell 
survival signaling and human IL-15 for NK cell activation (17,30). Tumors are imaged on day 
fourteen and twenty-one, and we see that mice receiving the BiKE treatment have prolonged 
survival and tumor clearance than the control (Fig. 4). However, IL-2 has been shown to 
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independently activate NK cell cytotoxicity by upregulating the amount of NKG2D expressed 
on the surface of NK cells, so we are unable to attribute tumor cell clearance solely with the 
BiKE treatment (17). In addition, by injecting both human NK cells and BiKE into the mice, 
we are manipulating the murine immune system, introducing further variability into our 
experiment. To generate further preclinical data and potentially proceed to clinical trials, an 
immunocompetent mouse model system must be created to test our BiKE construct. 
NKG2D Signaling Differences in Humans and Mice 
NKG2D is a C type-like lectin single-pass transmembrane protein that forms 
homodimers in the plasma membrane. In humans, NKG2D noncovalently associates with 
four DNAX-activated protein of 10 kD (DAP10) subunits in the lipid bilayer through a critical 
aspartic acid residue and form salt bridges with the arginine residue in the transmembrane 
domain of NKG2D (31,32). Wu et. al. has shown that this NKG2D-DAP10 complex stably 
associates together in humans, and the expression of DAP10 is required to stabilize NKG2D 
Figure 4. Timeline of murine BiKE testing. Irradiated mice are injected with MM cells and then injected with human NK 
cells, IL-2, IL-15, and either control BiKE or anti-CS1 BiKE daily for two weeks. On the left, tumor growth is shown using 
bioluminescent dye in a mice treated with control BiKE, while no tumor growth is seen on the mouse on the right 
receiving anti-CS1 BiKE treatment. 
Figure 4. BiKE In Vivo Testing 
18 
 
expression (33). NKG2D recognizes cell surface ligands upregulated by stress, typically from 
viral infection, tumorigenesis, and DNA damage (33). When NKG2D binds one of its 
activating ligands, including major histocompatibility complex (MHC) class 1-related ligands, 
stress-inducible surface glycoproteins MICA and MICB, and human cytomegalovirus UL16 
binding proteins (ULBPs), DAP10 becomes phosphorylated and causes a signaling cascade 
(34,35). Because one NKG2D homodimer associates with four DAP10 protein subunits, the 
signal is immediately amplified and increases NKG2D signaling sensitivity (36). The 
phosphatidylinositol 3-kinase (P1-3K) becomes phosphorylated and activates AKT, leading 
to a phosphorylation cascade that activates both NK cell cytotoxicity and INFγ cytokine 
release (Fig. 5) (32). In humans, there is only one NKG2D signaling pathway that leads to the 
specific lysis of target cells and IFNγ release to activate other cytolytic effector cells and 







In mice, there are two separate NKG2D signaling pathways with two alternatively 
spliced versions of NKG2D. The first protein, called NKG2D-long (NKG2D-L) works in a 
similar manner to humans; NKG2D-L signals through DAP10 and activates the PI3 kinase for 
Figure 5. Differences between murine and human NKG2D signaling. In mice, two 
transcript variants of NKG2D control signaling through DAP10/12. In contrast, human 
NKG2D only has one transcript that controls NKG2D signaling using only DAP10. 
Figure 5. NKG2D Signaling in Mice and Humans 
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downstream signaling, but only cell cytotoxicity is activated.  There is a second protein, 
called NKG2D-short (NKG2D-S), which is missing thirteen amino acids at the N terminus 
compared to NKG2D-L and is only translated when the NK cell has already been activated by 
other signaling pathways (Fig. 5)(12,37). Studies show that there is significant sequence 
divergence in human NKG2D and murine NKG2D transmembrane domains, allowing murine 
NKG2D to associate with both DAP10 and DAP12. When NKG2D-S pairs with DAP10, it still 
activates the NK cell cytotoxicity pathway. However, pairing with DAP12 initiates IFNγ 
release through the spleen tyrosine kinase (Syk) and NFκB signaling pathways (12,32,37). 
Using the NKG2D-S pathway, both cell cytotoxicity and IFNγ release can be initiated like the 
human signaling pathway, but it uses both DAP10 and DAP12 to accomplish both signaling 
pathways. Murine NKG2D also binds different ligands, many of which are homologs to 
human NKG2D signaling molecules, including retinoic acid-early (RAE-1) molecules, 
histocompatibility antigen 60 (H60), murine UL16-binding protein-like transcript 1 
(MULT1), and major histone compatibility complex homologs (34,38). Because the 
extracellular binding domains of NKG2D bind different ligands in humans and mice, our 
human BiKE protein is unable to bind murine NKG2D and subsequently is affecting the 
quality of our in vitro testing data. 
NKG2D Specific Tumor Evasion Methods 
Tumor cells have developed many techniques to dampen the anti-tumor of effects of 
the NKG2D receptor. One such mechanism is by secreting tumor growth factor (TGF)-β, an 
anti-inflammatory cytokine. TGF-β deactivates NKG2D signaling in a dominant fashion, 
overriding the presence of NKG2D ligands and upregulating NKG2D cytokines, such as IL-2 
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and IL-15, which stabilize DAP10 expression levels by promoting glycosylation (17,39). It 
has been shown that TGF-β downregulated NKG2D expression on cytotoxic lymphocytes by 
decreasing DAP10 transcription via interfering with the RNA Polymerase II association with 
the DAP10 promoter (17,39). It has also been shown that TGF-β disrupts the ratio of CD16dim 
and CD16bright NK cells, skewing the overall NK cell population to CD16dim NK cells with low 
expression levels of NKG2D (40). TGF-β constitutes a major pathway by which cancerous 
cells decrease NKG2D anti-tumor activity. 
Another pathway by which cancer cells downregulate NKG2D receptor expression is 
by maintaining high levels of cell-surface bound NKG2D ligands. Studies have demonstrated 
that some cancer patients with tumors expressing high levels of NKG2D ligands had NK cell 
populations with decreased NKG2D expression, specifically in thymomas patients with high 
NKG2D ligand expression (41,42). Mouse studies have also confirmed this observation; mice 
that constitutively expressed MICA and RAE-I ligands had NK cell populations that were 
unable to reject RAE-I expressing tumors (41). Researchers have proposed that, while 
initially NKG2D ligand-expressing tumors may easily be rejected by NK cells, constitutive 
expression of these ligands leads to a knockdown of NKG2D expression, internalization of 
NKG2D receptors on cytotoxic lymphocytes, or dampens the NKG2D signaling pathway and 
response (39,41). As a result, tumors with continually high NKG2D ligand expression pose a 
clinical challenge to oncologists and their patients. 
The discovery that tumor cells often shed NKG2D ligands, by either cleaving surface 
proteins or exocytosing alternatively-spliced soluble versions of the ligands, has further 
complicated researchers’ model of NKG2D tumor cell evasion. Evidence shows that soluble 
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MICA secreted by tumors decrease NKG2D responsiveness, either by overstimulating the 
NKG2D pathway and leading to decreased expression or endocytosis of the receptor, or by 
occupying the NKG2D receptor site and preventing it from interacting with NKG2D ligands 
on the surface of tumor cells (43). Another study used a mouse line with constitutive 
expression of soluble MULT1 and tumors expressing Rae-1 ligands to test this hypothesis. 
Their results show that soluble MULT1 decreased NKG2D- mediated cell killing by causing 
endocytosis of NKG2D receptors and blocking NKG2D binding sites, but this activity was 
recovered when mice were treated with anti-MULT1 antibodies (12). Evidence shows that 
inflammatory cytokines can overcome this effect by increasing NKG2D expression, and we 
hypothesize that our BiKE will have a similar effect overcoming this type of immune evasion 
(43). However, NKG2D shed ligands are a recent discovery, and some reports have found 
that shed ligands increase NKG2D sensitivity by upregulating the expression of NKG2D and 
lead to better tumor rejection (44). In addition, it has also been reported that MM cells shed 
CS1-soluble ligands, but research has not shown if this has an effect on immune evasion or 
NKG2D surface expression (45). Further research must be conducted to gain a better 
understanding of the NKG2D shed ligand’s role in immune evasion.  
NKG2D Chimeric Protein Project 
Previous studies indicate that human NKG2D may be able to initiate signaling in a 
murine NK cell due to 76% DAP10 sequence homology between species, conserved PI-3 
kinase phosphorylation domains in DAP10 between species, and human NKG2D co-
localization with both murine and human DAP10 (32). However, when our lab tested human 
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NKG2D signaling in murine NK cells neither IFN-γ release or cell cytotoxicity was observed 
(Fig. 6).  
 
In light of these experiments, we created a chimeric NKG2D protein that would bind to 
the human anti-NKG2D anti-CS1 BiKE protein and initiate an intracellular murine NKG2D 
response. The chimeric NKG2D construct has the extracellular domain of human NKG2D, the 
transmembrane domain of murine NKG2D-S, and the intracellular domain of murine NKG2D-
S. This construct will bind the human BiKE protein, pair with both DAP10 and DAP12 in 
murine NK cells, and mount a murine immune response leading to both cell cytotoxicity and 
IFNγ release. Here, I report our findings on:  
1. Chimeric NKG2D expression in murine NK cells; 
2. Evaluation of BiKE binding to the NKG2D chimeric construct; 
Figure 6. Human NKG2D expressed in mouse NK cells showed no IFN-γ release. Murine NK cells showing human 
NKG2D expression were stained with gold-standard anti-human NKG2D antibodies and crosslinked with goat 
anti-mouse antibodies. A golgi transport inhibitor was added to prevent IFN-γ exocytosis. Control and treatment 
groups showed no difference in IFN-γ levels. 
Figure 6. Human NKG2D Binding in Murine NK Cells  
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3. Evaluation of the function of BiKE binding to the NKG2D chimeric construct. 
Results from these in vitro experiments will provide the data necessary to proceed towards 
creating a chimeric NKG2D knock-in mouse model and preclinical BiKE testing in vivo. To 


























BiKE antibody construction, expression, and purification 
Our BiKE was designed in silico using DNA from the mouse anti-human NKG2D and 
anti-human CS1 single chain variable fragment monoclonal antibodies joined by a non-
immunogenic human aldose protein linker. A secretory H7 signal peptide was added to the 
N-terminus of the protein sequence, and a six-histidine tag was added to the c-terminus of 
the anti-CS1 single chain variable fragment. After codon optimization, the sequence was 
synthesized and subcloned into a pCDH lentiviral vector with a GFP reporter gene to 
characterize expression levels (SBI Bioscience, Palo Alto, CA, USA). A CHO-S cell line 
(Invitrogen, Waltham, MA, USA) was created by sorting for highly GFP expressing cells using 
BD Aria II (BD Biosciences, San Jose, CA, USA). A CDR3 deletion mutation was made to create 
a negative binding bispecific antibody control (control BIKE). The supernatant of CHO-S 
cultures was purified and concentrated using size-exclusion chromatography. Samples were 
sequentially dialyzed with PBS using 100 and 50 kDa pore filters. Purified BiKE was then 
analyzed by SDS-PAGE and stained with Coomassie Brilliant Blue for size estimation and 
quality control. Protein concentration was calculated using the NanoDrop 2000 (Thermo 
Ficher Scientific, Watham, MA, USA). 
Multiple myeloma cell, murine natural killer cell, human natural killer cell, and 293T cell 
cultures 
The multiple myeloma cell line MM.1S was obtained from ATCC (Manassas, VA, USA) 
and cultured under the manufacturer’s instruction. A murine liver natural killer cell line 
(LNK) was obtained from Dr. Jianhua Yu and cultured in RPMI with 10% FBS, 5% sodium 
pyruvate, 0.1% BME, and 6.7 µL/mL IL-2. All cell lines were routinely checked for 
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mycoplasma and passaged for no more than two months. Human peripheral blood 
mononuclear cells (PBMCs) were isolated from the peripheral blood of healthy donors by 
Ficoll-Paque Plus (GE Healthcare Life Science) gradient density with the approval of the 
Institutional Review Board at The Ohio State University. Human NK cells were isolated from 
peripheral blood using the RosetteSep human NK isolation kit (Stem Cell Technology, 
Cambridge, MA, USA) following the manufacturer’s instructions. Primary murine natural 
killer cells were isolated from the spleen of C57BL/6 sacrificed mice. Spleen were 
homogenized and filtered through 100um cell strainer. The NK Cell Isolation Kit II, a negative 
murine NK selection kit, was used to select for murine NK cells according to manufacturer 
instructions (Milenyi Biotec, Auburn, CA, USA). Murine NK spleen cells were cultured in 
RPMI with 10% FBS and 3.3 µL/mL IL-2. 293T cells were obtained from SBI Sciences and 
were cultured in DMEM medium with 10% FBS and confluency was maintained.  
NKG2D vector design 
mRNA from human and murine NK cells was isolated and the NKG2D gene was 
amplified using a cDNA reverse transcriptase kit,  Vilo cDNA Synthesis Kit (ThermoFisher 
Invitrogen, Watham, MA, USA). From this DNA, three NKG2D viral vectors were made using 
a pCDH lentiviral vector: a control vector, a full length human NKG2D vector, and a chimeric 
NKG2D vector. The control vector simply had an empty pCDH vector with no NKG2D DNA 
introduced. The full length human NKG2D vector (NKG2D-full) used restriction sites to insert 
the full human NKG2D cDNA sequence into the pCDH vector. The third vector, the chimeric 
NKG2D vector (NKG2D-chim), was constructed to have an extracellular human NKG2D 
binding domain, a murine NKG2D-S transmembrane domain, and murine intracellular 
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signaling domain (Fig. 7). Restriction enzyme cut sties were inserted into the human and 
murine NKG2D sequences using PCR-directed mutagenesis to ligate the sequences together. 
The DNA for the vectors was subcloned into the pCDH vector.  We redid our NKG2D-chim 
DNA sequence after finding errors in the 
protein binding domains created with 
misdesigned primers. This DNA sequence had 
the same structure as NKG2D-chim vector, but 
restriction sites were not inserted into the 
sequence and the DNA sequence was codon 
optimized for murine expression. NKG2D-
chimR was synthesized by Quintarabio into a 
pCDH vector. All vectors were sequenced using The Ohio State University Comprehensive 
Cancer Center Sanger Sequencing services.  
Next, the vectors were transfected into 293T cells using Lipofectamine according to 
the manufacturer’s instructions. The pCDH vectors were co-transfected with helper 
plasmids psPax2, a packaging viral vector, and pHDMG, a viral envelope vector, in an Opti-
MEM medium into 293T cell cultures. Sixteen hours after transfection, the Opti-MEM 
medium was exchanged for DMEM medium. Twenty-four hours later, the supernatant of the 
transfected 293T cells was collected and filtered for cellular debris through a 0.45µm filter, 
and the viral particles were concentrated using an ultra-centrifuge and a sucrose cushion at 
25,000 RPM for 2 hours at 4°C. The virus is then resuspended in X-Vivo 15 medium and a 
viral titer was performed to measure the concentration of virus. For the titering experiment, 
Figure 7. Design of the chimeric NKG2D 
receptor. cDNA for the murine NKG2D-S 
cytoplasmic and transmembrane was joined 
with cDNA for the human NKG2D ectodomain. 
Figure 7. Chimeric NKG2D Receptor 
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293T cells are again used and the virus is serially diluted. Concentration is measured by GFP 
expression of 293T cells using a BD LSRII flow cytometer. Viral stock is then stored at -80°C. 
Viral transduction of murine natural killer cells 
Murine NK cells are transduced with virus in a 96-well plate. After twenty-four hours, 
the NK cells undergo a second round of transduction. NK cells are then harvested 24 hours 
later and suspended in RPMI medium with 10% FBS, 5% sodium pyruvate, 0.1% BME, and 
6.6 µL/mL of IL-2. After three days, NK cells were checked for vector GFP expression and 
sorted using a BD LSRII flow cytometer. 
Murine natural killer liver cells and BiKE cytotoxicity assays 
Murine LNK cells transduced with control and NKG2D-chim vectors were plated in a 
20:1 ratio with MM.1S tumor cells. Cells were either treated with PBS, 10 µg/100 µL of 
control BiKE, or 10 µg/100 µL BiKE in 10% FBS and 1% antibiotic RPMI medium in a flow-
based cytotoxicity assay. LNK NKG2D-chim cells incubated with PBS or control BiKE were 
used as a negative control. The plate was incubated for 24 hours. During flow cytometry 
sorting, NK cells were identified as GFP positive due to the expression of the GFP gene in the 
pCDH lentiviral vector while MM.1S cells were stained for human CD45 and sytox to 
determine the percentage of tumor clearance.  
Primary murine natural killer spleen cells and BiKE cytotoxicity assays 
Murine spleen cells transduced with control, NKG2D-full, and NKG2D-chim vectors 
were plated in a 20:1 ratio with MM.1S tumor cells and 10 µg/100 µL BiKE in 10% FBS and 
1% antibiotic RPMI medium in a flow-based cytotoxicity assay. Multiple myeloma cells 
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incubated with BiKE were used as a negative control. The plate was incubated for 24 hours. 
During flow cytometry sorting, NK cells were identified as GFP positive while MM.1S cells 
were stained for human CD45 and sytox to determine the percentage of tumor clearance.  
293T cell binding assay for BiKE 
293T cells were transformed with the control vector and the NKG2D-chimR vector 
using lipofectamine according to manufacturer instructions. After 16 hours the cells were 
checked for transient expression of NKG2D. Cells were washed with MACS buffer, and both 
the control and the NKG2D-chimR cells there were four staining groups: isotype APC, human 
anti-NKG2D, control BiKE conjugated with APC, and BiKE conjugated with APC. After 
incubation in the dark for twenty minutes at room temperature, the cells were washed with 






pCDH NKG2D-full and NKG2D-chim vector subcloning 
To create a vector expressing the full length human NKG2D 
cDNA, PCR was performed with primers introducing restriction 
enzyme sites for ligation into the pCDH vector. An EcoR1 site was 
added at the 5’ end of the amplified gene, while a Not1 restriction 
enzyme was added at the 3’ end of the gene. PCR showed 
successful amplification of the 650 base pair gene (Fig. 8), and the 
fragment was then digested by restriction enzymes and then 
ligated into the pCDH vector with T4 DNA ligase. LNK and 
murine NK spleen cells were transduced with the vector, and 
GFP expression confirmed plasmid integration and gene 
expression during transduction experiments (Fig. 11).  
The chimeric NKG2D vector was subcloned into pCDH in 
a similar manner. Both murine NKG2D-S and human NKG2D 
cDNA was amplified using PCR primers that inserted restriction 
enzymes into the sequence for subcloning. For the murine 
intracellular and transmembrane domains, an EcoR1 cut site 
was introduced on the 5’ end of the sequence, and a BamH1 site 
was introduced at the 3’ end. The human NKG2D extracellular 
domain was amplified with BamH1 at the 5’ end and Not1 at the 3’ end. PCR showed 
successful amplification of a 252 base pair fragment of murine NKG2D-S cDNA and a 435 
Figure 8. Full length NKG2D PCR 
from healthy NK donor cells. Both 
lanes show PCR products from 
two different donors, with a PCR 
product around 650 base pairs. 
Figure 8. Full Length 
Human NKG2D PCR 
Figure 9. PCR amplification of the 
murine NKG2D intracellular and 
transmembrane domains (Lane 1) 
and the human NKG2D ectodomain 
(Lane 2). The murine NKG2D 
fragment is approximately 250 base 
pairs and the human NKG2D fragment 
is approximately 450 base pairs. 




base pair fragment of human NKG2D (Fig. 9). Each fragment was digested with their 
respective restriction enzymes and ligated into a pCDH vector. LNK and murine NK spleen 
cells were transduced with the NKG2D-chim vector, and GFP expression confirmed plasmid 
integration and gene expression during transduction experiments (Fig. 11). High GFP 
expression was correlated with high protein construct expression (either human NKG2D or 
chimeric), so we sorted for GFP expression. We did not sort with anti-human NKG2D 
antibodies because they prematurely activate the murine NK cells and can alter the results 
of our functionality assays. 
The NKG2D-chimR vector was sent for sequencing, so only GFP expression had to be 
confirmed during transduction to show gene expression (Fig. 11). 







LNK NKG2D-chim cells were incubated with PBS, control BiKE, and BiKE in the 
presence of MM cells and tested for tumor clearance. LNK NKG2D-chim cells were found to 
have lower MM tumor clearance, but these results were not statistically significant (p=0.1) 
Figure 10. LNK chimeric cells were seeded in a 20:1 ratio with MM cells and 
treated with PBS, control BiKE, and BiKE to test the specific lysis of MM cells. 
Figure 10. Chimeric NKG2D LNK Cell Cytotoxicity Assay 
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(Fig. 10). This indicates that the chimeric receptor is not functioning properly in LNK cells. 
These results are representative of other LNK chimeric receptor cell cytotoxicity assays. 
Primary murine natural killer spleen cells and BiKE cytotoxicity assays 
Murine NK spleen cells were transduced with the empty pCDH vector, NKG2D-full 
vector, and NKG2D-chim vector plasmids (Fig. 11). Cells were analyzed with flow cytometry 
to check the percentage of transduced cells indicated by the GFP expression. The cells were 
then subsequently sorted using BD Aria II cell sorter to sort all transduced cells. These cells 










After incubating the murine NK cell control, NKG2D-full, and NKG2D-chim with MM 
cells and BiKE for 24 hours we found that the NKG2D-chim cell lines exhibited statistically 
Figure 11. Transduced murine NK cells were sorted for empty vector, 
NKG2D-full, and NKG2D-chimR GFP expression using flow cytometry. 
Figure 11. Primary Murine Spleen Cell Transduction 
32 
 
significant tumor clearance (more than 12%) than the NKG2D-full and control cell lines 







Transmembrane domain comparison between NKG2D-chim and redesigned NKG2D-chim R 
vector 
Upon comparing our sequence data between our NKG2D-chim vector and our desired 
chimeric receptor (later called NKG2D-chimR), we found two errors in the DNA sequence. 
As shown in Figure 13, a segment of the murine extracellular domain was added to the 
sequence in between the murine transmembrane domain and the BamH1 cut site used to 
create the vector. In addition, part of the human extracellular domain was absent from the 
sequence in the NKG2D-chim vector, as shown in Figure 14. The new vector, NKG2D-chimR, 
was designed to contain only the murine NKG2D-S transmembrane domain and the human 
NKG2D extracellular domain as originally intended. The NKG2D-chimR vector was 
constructed at Quantarabio to correct the sequence and eliminate the restriction enzyme cut 
sites. 
Figure 12. Murine NK cells transduced with an empty pCDH vector, NKG2D-full, and NKG2D-chim were 
incubated with BiKE and MM cells for 24 hours. Percentage of tumor clearance was observed. 
*** 













Figure 13. The DNA sequence for the NKG2D-chim receptor is compared with the NKG2D-chimR 
sequence. The NKG2D-chim vector correctly contains a murine NKG2D-S transmembrane domain, 
a BamH1 restriction enzyme cut site, and a human NKG2D extracellular domain. However, when 
compared with the NKG2D-chimR sequence, we see that NKG2D-chim sequence incorrectly 
contains a murine extracellular domain. 
Figure 13. DNA Comparison between NKG2D-chim and NKG2D-chimR 
Vectors 
Figure 14. The protein sequence for the NKG2D-chim receptor is compared with the NKG2D-chimR receptor. 
The human extracellular domain in the NKG2D-chimR vector has been codon optimized for murine 
expression, but by comparing the protein sequences we see that the NKG2D-chim vector is missing eight 
amino acids (IWSAVFLN) from the human extracellular domain. 
Figure 14. Protein Comparison between NKG2D-chim and NKG2D-chimR Vectors 
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293T cell NKG2D-chimR binding assay 
293T cells transiently expressing NKG2D-chimR vector were tested for human 
NKG2D binding using human NKG2D ligands, including anti-human NKG2D antibodies and 
our BiKE. Both treatments have an increase in mean fluorescence intensity (MFI) when 
compared to the isotype control (Fig. 15). These results indicate that our newly designed 





Figure 15. NKG2D-chimR transfected 293T cells stained for human NKG2D using anti-human 
NKG2D antibodies and fluorescent BiKE antibodies. Both treatments show a shift in 
fluorescence, indicating NKG2D-chimR expression and binding with human NKG2D ligands. 





Multiple myeloma is an incurable hematological malignancy with over 30,000 
diagnoses per year (5). With limited treatment options, many MM patients face ongoing 
chemotherapy treatments and drug side effects that affect their quality of life. Recently, the 
field of immunotherapy has created opportunities to redirect the immune system against 
MM, and our lab has capitalized on this by creating a MM-specific BiKE. BiKE is a bispecific 
antibody targeting both CS1, a receptor highly expressed on MM tumor cells, and NKG2D, 
and activating receptor on NK, NKT, and T cells. While our lab has shown BiKE to be effective 
in vitro, our in vivo model does not accurately model a BiKE drug response, and this 
preclinical data is critical to begin testing BiKE for the FDA. Thus, an immunocompetent 
mouse model must be created to test BiKE in vivo. 
The purpose of this study was to make and test a chimeric NKG2D receptor 
functionality to make a mouse model to test BiKE efficacy in mice. We hypothesized that by 
creating a chimeric NKG2D protein, we could create a mouse model that expresses chimeric 
NKG2D on NK, NKT, and T cells naturally in the murine immune system, respond to human 
NKG2D ligands, and activate NK cells through IFNγ release and cell cytotoxicity. Specifically, 
we wanted to create an immunocompetent mouse model that could respond to our anti-
NKG2D and anti-CS1 BiKE protein. This mouse model is critical to produce preclinical in vivo 
data about BiKE to lend support for BiKE clinical trials and could also be used to test other 
aspects of human NKG2D in a mouse model. 
To test our construct, we expressed our chimeric protein in LNK and primary murine 
spleen NK cells to test NKG2D functionality through cell cytotoxicity, a key action of NK cells 
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to lyse target cells. While our LNK cytotoxicity assay did not show statistically significant 
killing of MM cells, our primary murine NK cell assay did show significant MM cell lysis. 
Although we demonstrated that primary murine NK cells elicit a tumor killing response, 
there was concern that the response may not be as strong as human NK cells incubated with 
BiKE. While we later found that the chimeric protein used in these experiments was faulty, 
the positive results in the primary murine NK cells bode well for our continuing experiments 
with our redesigned protein. Now that we have redesigned the chimeric protein we are 
optimistic that it may elicit a stronger tumor killing response and prove a promising 
candidate for a murine mouse model.  
While our LNK chimeric protein cytotoxicity assay was unsuccessful, the same 
experiment in primary murine NK cells lended statistically significant results. We believe 
this may be due to functional differences in the LNK cell line. While the LNK cell line is 
immortalized, simple to culture, and is easier to transduce than primary NK cells, there is 
limited data on the functionality of the LNK cell line in the literature (46,47). So, we began 
using primary spleen murine NK cells instead to better model the functionality of murine NK 
cells. However, this has presented challenges because primary cells are not immortalized 
and they are difficult to transduce (47). Ultimately, we decided it was better to accurately 
model the functionality of murine NK cells, perhaps explaining the different results in the 
cytotoxicity assays. 
When redesigning our chimeric protein, we found that our NKG2D-chim vector 
contained an extraneous murine NKG2D-S extracellular domain and a human NKG2D 
extracellular domain deletion. The DNA sequence was then corrected and to improve 
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functionality the restriction enzymes cut sites were removed. Currently, the sequence 
contains the murine NKG2D-S intracellular and transmembrane domains and the human 
NKG2D ectodomain. As a result, the redesigned protein should bind human NKG2D ligands, 
such as BiKE, with the human ectodomain while also associating with both murine DAP10 
and DAP12 using the murine NKG2D-S transmembrane and intracellular domains. Our 
results also support previous literature indicating that species-specific NKG2D association 
with DAP10 occurs in the transmembrane domain (32). By utilizing the murine NKG2D-S 
transmembrane domain in our chimeric protein, we were able to induce cell cytotoxicity 
using human ligands, indicating that the transmembrane domain, not the extracellular 
domain, is important for this signaling process.  
Finally, we tested the ability of BiKE and anti-human NKG2D antibodies to bind to our 
chimeric receptor. To elicit an immune response, the chimeric construct must bind human 
NKG2D ligands, so we use flow cytometry and fluorescent ligands to examine this binding. 
In a previous pilot study, our lab showed that primary murine NK cells expressing the 
NKG2D-chim vector did not bind human NKG2D ligands (data not shown). However, when 
we transiently transformed 293T cells with the redesigned NKG2D-chimR vector, we saw 
the expression of NKG2D and binding of both BiKE and anti-human NKG2D antibodies. These 
results indicate that our chimeric protein can bind human ligands and also indicate that our 
chimeric protein may better respond to ligands to produce both cell cytotoxicity and IFNγ 
release. Looking forward, we are optimistic that the new chimeric NKG2D protein will 
provide stronger cell cytotoxicity and IFNγ release. 
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One limitation in this study is our initial NKG2D-chim trials in LNK cells did not lend 
statistically significant data showing NKG2D activation. However, using the primary murine 
NK cells we were able to overcome this limitation. In addition, we had a small number of 
trials and cell numbers for our experiments due to the toxicity of the NK cell transduction 
process. Literature shows that lentiviral transduction is the most effective means of 
expressing foreign DNA in NK cells, but these methods are still only 15% effective, decreasing 
the number of cells we can use for our experiments (47). Finally, the misdesigned chimeric 
protein used in the cell cytotoxicity assay prevents us from further interpreting negative 
results. However, the chimeric protein has been redesigned so moving forward with the 
project we will be better able to interpret our results. Despite these limitations, positive 
results from binding assays in transient 293T cells indicate the validity of our methods and 
the potential for this project’s future success. 
In conclusion, our chimeric NKG2D protein has been shown to bind human NKG2D 
ligands and initiate a cytotoxic response. While more testing must be conducted on our 
NKG2D-chimR vector, we are optimistic that this data will support the creation of a chimeric 
NKG2D knock-in mouse model. This murine model will express NKG2D in NK, NKT, and T 
cells, creating a more accurate model of the activating effects of BiKE in vitro than NK cells 
alone. In addition, this model will allow us to stop injecting human NK cells into mice to test 
BiKE, reducing the amount of error we are introducing into our modeling system. Due to 
BiKE’s modular design, other researchers may continue to use an anti-NKG2D BiKE therapy 
targeting different cancer targets for other cancer therapies. If so, creating this mouse model 
will serve to expedite other BiKE clinical and translational research projects. To the best of 
our knowledge, there is no other mouse model available expressing a chimeric NKG2D 
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receptor. Finally, in addition to helping test BiKE, the mouse model may serve as a better 
system to study human NKG2D cell responses in vitro, fulfilling a need in the greater scientific 
community. By creating this model, we are one step closer to providing BiKE therapy to 






Since we have confirmed our new NKG2D-chimR receptor can bind BiKE in 293T cells, 
our next step would be to create viral NKG2D-chimR particles and transduce murine NK cells. 
Once we see GFP expression in the cells, we would retest the binding of BiKE to the 
transduced receptor. Given our previous results with 293T cell expression, we expect that 
our construct will still bind in murine NK cells. If, however, it does not bind BiKE, this would 
point towards post-transcriptional mechanisms preventing expression of the chimeric 
receptor on the surface of the cell. If this occurred, we would investigate mRNA levels of our 
chimeric receptor, glycosylation of the protein, and protein trafficking through the ER. 
Next, we would test the redesigned chimeric receptor’s ability to induce a cytotoxic 
response to reject tumor cells. In this experiment, we would utilize human NK cells as a 
positive control, our empty vector murine NK cells as a negative control, and murine NK cells 
expressing our chimeric receptor as our test cell line. These cell lines would be seeded with 
multiple myeloma tumor cells (MM1.s), and there would be both a control group receiving 
our control BiKE and a group receiving a BiKE treatment. The assay would be read by the BD 
LSRII flow cytometer, as described earlier in the methods. We would look for statistically 
significant tumor clearance in the chimeric cell line receiving a BiKE treatment, similar to the 
tumor cell clearance of human NK cells with a BiKE treatment. If this experiment does not 
show tumor clearance, we would investigate the downstream signaling pathway of NKG2D 
in mice to see which parts of the signaling pathway are disrupted. This would include testing 
the downstream phosphorylation of murine DAP10 and the PI3 kinase. If these signaling 
pathways are not activated, we may have to redesign the transmembrane domain of the 
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chimeric protein to ensure activation of these pathways. If the cytotoxicity assay works, then 
we will proceed to test IFNγ release. 
To test IFNγ levels, we would perform a crosslinking assay to induce IFNγ production. 
Here again we would utilize human NK cells, murine NK cells with an empty vector, and 
murine NK cells expressing the redesigned chimeric NKG2D receptor. Each cell line would 
be incubated with anti-human NKG2D antibodies, and then subsequently incubated with 
anti-human mouse antibodies. Using a golgi plug to block the release of the IFNγ to medium, 
we would determine the IFNγ expression levels using flow cytometry and staining for 
intracellular IFNγ. We can also perform an ELISA experiment using the supernatant from the 
cytotoxicity assay cultures to determine IFNγ levels. If these experiments are not showing 
the release of IFNγ, then we will examine the downstream signaling of murine DAP12, 
including the phosphorylation of DAP12, phosphorylation of Syk kinase, and the production 
of NFκB. We also would check for coimmunoprecipitation of Syk kinase with DAP12 and our 
NKG2D-chimR receptor. If these signaling pathways are not being activated, we may need to 
redesign the transmembrane domain of our chimeric NKG2D protein.  
If found that neither the cytotoxicity assays or the IFNγ assays are showing NKG2D 
activation, then we will consider co-transducing human DAP10 into murine NK cells with the 
full length human NKG2D receptor. We also will investigate the processing of our chimeric 
NKG2D receptor, including intracellular trafficking and glycosylation. However, if our assays 
show that our NKG2D chimeric receptor is activating murine NK cells, we will proceed to 
make a heterozygous knock-in mouse model to test BiKE in vivo using the OSU Genetically 
Engineered Mouse Model Core. We will repeat the same mouse experiment as described in 
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the intro, except we will not have to inject human NK cells into the mouse. This trial will 
generate preclinical data for BiKE and the data collected may even help move our BiKE 
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